Recursion (RXRX) CFO reports RSU tax withholding of 7,057 shares on Form 4

Rhea-AI Filing Summary

Recursion Pharmaceuticals, Inc. reported an insider equity transaction by its Chief Financial Officer on 12/15/2025. The filing shows that 7,057 shares of Class A common stock were disposed of at $4.33 per share. According to the footnote, these shares were withheld by the company to cover tax withholding and remittance obligations related to the net settlement of restricted stock units, rather than an open-market sale.

After this tax withholding event, the reporting person beneficially owned 782,933 shares of Class A common stock directly. The transaction is characterized with code "F," which typically denotes payment of tax liability by withholding securities incident to vesting of equity awards.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Taylor Ben R

(Last) (First) (Middle)

41 S. RIO GRANDE STREET

(Street)

SALT LAKE CITY UT 84101

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
RECURSION PHARMACEUTICALS, INC. [ RXRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
12/15/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	12/15/2025		F(1)		7,057	D	$4.33	782,933	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units.

Remarks:

	/s/ Kyle Nelson, attorney-in-fact	12/17/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Recursion Pharmaceuticals (RXRX) disclose in this Form 4?

The company disclosed that its Chief Financial Officer had 7,057 shares of Class A common stock withheld on 12/15/2025 at $4.33 per share to satisfy tax withholding obligations related to restricted stock units.

How many Recursion Pharmaceuticals (RXRX) shares does the reporting person own after the transaction?

Following the reported transaction, the reporting person beneficially owned 782,933 shares of Recursion Pharmaceuticals Class A common stock, held in direct ownership.

Was the Recursion Pharmaceuticals (RXRX) Form 4 transaction an open-market sale?

No. The filing explains that the 7,057 shares were withheld by the issuer to meet tax withholding and remittance obligations from the net settlement of restricted stock units, rather than sold in an open market trade.

Who is the insider involved in this Recursion Pharmaceuticals (RXRX) Form 4 filing?

The insider is an officer of Recursion Pharmaceuticals, specifically the Chief Financial Officer, as indicated in the relationship section of the filing.

What does transaction code "F" mean in the Recursion Pharmaceuticals (RXRX) Form 4?

The transaction code "F" in this context indicates a transaction where shares are withheld by the issuer to satisfy tax withholding obligations arising from the vesting or settlement of equity awards such as restricted stock units.

Does the Recursion Pharmaceuticals (RXRX) Form 4 mention Rule 10b5-1?

The form includes a checkbox to indicate if a transaction was made under a Rule 10b5-1(c) trading plan. The excerpt shows this checkbox language, but does not indicate that the box was checked.